ArticleCancer research2022

A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer.

Yara Rodríguez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.